Medication for pediatric psychiatric disorders reduces later onset of substance use problems
Early and longer-lasting treatment reduces risk of substance use disorder most significantly.
Safe Care CommitmentGet the latest news on COVID-19, the vaccine and care at Mass General.Learn more
Research at Massachusetts General Hospital includes multitude of hospital-wide centers, institutes and programs as well as collaborations with other institutions.
Early and longer-lasting treatment reduces risk of substance use disorder most significantly.
Combining the approaches may be a powerful anti-cancer strategy.
Preventing medication administration errors and improving efficiency during surgery enhances patient care.
Researchers uncover how the immune system clears, or in some cases helps, bacteria after infection.
ACTIVATE trial generated positive safety and efficacy data for mitapivat.
Important new clues about the genetic basis of schizophrenia have emerged in a landmark study led by investigators at the Analytic and Translational Genetics Unit (ATGU) at MGH and the Broad Institute of MIT and Harvard.